Skip to main content

Thermo Fisher to Sell Lab Workstations Business

NEW YORK (GenomeWeb News) – Thermo Fisher Scientific said after the close of the market on Thursday that it intends to sell its laboratory workstations business within the next 12 months.

In a document filed with the US Securities and Exchange Commission, the company said that senior management had made the decision to sell the "non-core" business on June 22. The laboratory workstation business is part of Thermo Fisher's Laboratory Products and Services Segment, and in 2011 it had revenues of $180 million and an operating loss of about $6 million, net of restructuring costs of $4 million.

Thermo Fisher will report the financial results for the business as discontinued operations beginning in the second quarter of 2012. During the quarter, it expects to record an after-tax charge of $50 million as the estimated loss on the planned sale.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.